For Research Use Only

Syn-AKE 200mg (Topical)

$230.00

Syn-AKE is a research peptide modeled after Waglerin-1, a peptide found in temple viper venom, designed as a tripeptide analog that targets nicotinic acetylcholine receptor (nAChR) subunits in experimental systems. Preclinical studies indicate that Syn-AKE modulates neuromuscular signal transduction and ion channel receptor activity, providing a model for studying peptide–receptor interactions and synaptic transmission. It is utilized in biochemical and dermatological research exploring peptide-based receptor modulation and neurochemical signaling pathways.

For research use only. Not for human consumption.

References:
Nirthanan S et al., Biochim Biophys Acta, 2003 1645(1):81–89
Utkin YN, Toxicon, 2013 71:133–155
Tsetlin V et al., Annu Rev Pharmacol Toxicol, 2015 55:319–341

SKU: sem-1-115 Category:

Overview

Syn-AKE is a synthetic tripeptide supplied exclusively for laboratory research applications. The peptide is structurally derived from a bioactive fragment of Waglerin-1, a venom-associated peptide originally isolated from the Malaysian Temple Viper (Tropidolaemus wagleri). In experimental systems, Syn-AKE is investigated for its effects on neuromuscular signaling pathways through interaction with nicotinic acetylcholine receptors. All observations are limited to preclinical, in vitro, and animal-based research models.

Sequence (Three-Letter Code): β-Ala-Pro-Dab-NHBn · 2 Acetate
Molecular formula: C23H37N5O7
Molecular weight: 495.57 g/mol

Biochemical Characteristics

Syn-AKE is a low–molecular weight synthetic peptide designed to replicate the active pharmacophore of Waglerin-1 while excluding non-essential amino acid residues. The abbreviated sequence enables targeted interaction with neuromuscular receptor complexes in experimental preparations. Acetate counterions improve peptide stability and handling characteristics in laboratory settings.

Research Applications

Syn-AKE is utilized in research models to study modulation of neuromuscular signal transmission. In vivo animal studies and in vitro neuromuscular junction assays employ Syn-AKE to evaluate changes in muscle fiber activation resulting from competitive inhibition of acetylcholine-mediated signaling. These investigations support mechanistic characterization of peptide–receptor interactions at the synaptic interface.

Pathway / Mechanistic Context

Syn-AKE functions as a competitive antagonist of the muscular nicotinic acetylcholine receptor (nAChR). By binding to the receptor’s ligand recognition site, Syn-AKE inhibits acetylcholine-induced ion channel activation, thereby reducing depolarization at the neuromuscular junction. This reversible interaction allows controlled investigation of synaptic transmission dynamics and receptor occupancy in experimental systems.

Preclinical Research Summary

Preclinical studies involving Syn-AKE include animal models and in vitro neuromuscular assays evaluating peptide-mediated inhibition of acetylcholine receptor signaling. Experimental observations demonstrate transient, reversible modulation of muscle contractile signaling following exposure to Syn-AKE. These findings are used to characterize structure–function relationships of venom-derived peptide analogs without implication of applied or therapeutic outcomes.

Form & Analytical Testing

Syn-AKE is supplied as a synthetic research-grade peptide. Identity and purity are typically confirmed using analytical methods such as high-performance liquid chromatography (HPLC) and mass spectrometry (MS). Storage and handling should follow standard laboratory protocols applicable to synthetic peptides.

Referenced Citations

  1. Pickut, W. & Pickut, W. Side Effects of Syn-Ake. LIVESTRONG.COM Available at: http://www.livestrong.com/article/298145-side-effects-of-syn-ake/. (Accessed: 29th July 2016)
  2. Chhipa, N. M. R. & Chaudhari, B. TOXIN AS A MEDICINE. Available at: https://www.researchgate.net/profile/Nadim_Chhipa/publication/269037373_TOXIN_AS_A_MEDICINE/links/547dfbf70cf241bf4b5b9b40.pdf. (Accessed: 29th July 2016)
  3. Balaev, A. N., Okhmanovich, K. A. & Osipov, V. N. A shortened, protecting group free, synthesis of the anti-wrinkle venom analogue Syn-Ake® exploiting an optimized Hofmann-type rearrangement. Tetrahedron Lett. 55, 5745–5747 (2014).
  4. ZHMAK, M. N. et al. Peptide inhibitors of nicotinic acetylcholine receptor. (2015).
  5. Trookman, N. S., Rizer, R. L., Ford, R., Ho, E. & Gotz, V. Immediate and Long-term Clinical Benefits of a Topical Treatment for Facial Lines and Wrinkles. J. Clin. Aesthetic Dermatol. 2, 38–43 (2009).

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.

RUO Disclaimer

The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law.

For Laboratory Research Only. Not for human use, medical use, diagnostic use, or veterinary use.

Scroll to Top